Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eslicarbazepine Acetate Formulations
NCT03116321Phase 1Completed
- Sponsor
- BIAL
- Start
- Dec 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (3 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration at 72 hours, Area under the plasma concentration versus time curve from time zero to t at 72 hours and 1 more. Started Dec 2016; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03116321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116321.